Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Nov 16, 2021

PTC Therapeutics to Participate at Upcoming Virtual Investor Conference

SOUTH PLAINFIELD, N.J. , Nov. 16, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m. ET . The presentation will be webcast live on the

Oct 28, 2021

PTC Therapeutics Provides a Corporate Update and Reports Third Quarter 2021 Financial Results

- Total quarterly revenue of $139 million; 17% increase over third quarter 2020 - - Raises 2021 DMD franchise revenue guidance to $400-$420M from $370-$390M - - Continues to advance robust clinical pipeline by initiating a fifth registration-directed trial, APHENITY Phase 3 trial of PTC923 in

Oct 26, 2021

PTC Therapeutics to Participate at Upcoming Virtual Investor Conference

SOUTH PLAINFIELD, N.J. , Oct. 26, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, Nov. 9 at 8:00 a.m. ET . The presentation will be webcast live on the

Oct 25, 2021

PTC Announces Expansion of Translarna™ Label to Include Ambulatory Patients as Young as 2 Years Old in Brazil

SOUTH PLAINFIELD, N.J. , Oct. 25, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian National Health Surveillance Agency , ANVISA (Agência Nacional de Vigilância Sanitária), has approved the expansion of the indication of Translarna™ (ataluren) to include

Oct 14, 2021

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2021 Financial Results

SOUTH PLAINFIELD, N.J. , Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, Oct.

Oct 14, 2021

PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility

-- Expansion in New Jersey supports company's robust gene therapy pipeline to address devastating rare disorders -- SOUTH PLAINFIELD, N.J. , Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene

Oct 11, 2021

Tegsedi® Receives Innovative Drug Category Pricing in Brazil

SOUTH PLAINFIELD, N.J. , Oct. 11, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Tegsedi ® (inotersen) has successfully received Category 1 classification from Câmara de Regulação do Mercado de Medicamentos - CMED (Drug Market Regulation Chamber) in Brazil .

Sep 29, 2021

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , Sept. 29, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 22, 2021, the company approved non-statutory stock options to purchase an aggregate of 51,400 shares of its common stock and 18,790 restricted stock units ("RSUs"), each

Sep 29, 2021

Results Show Long-Lasting and Holistic Improvements in Children with AADC Deficiency Treated with PTC-AADC Gene Therapy

- Analysis of Five-Year Results Presented at 50th Child Neurology Society Annual Meeting - SOUTH PLAINFIELD, N.J. , Sept. 29, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented a new analysis of five-year results that shows its novel gene therapy, PTC-AADC,

Sep 20, 2021

PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program

SOUTH PLAINFIELD, N.J. , Sept. 20, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study. The new results include HTT mRNA and protein lowering, as well as PTC518 exposure levels in

Pagination

First page
Previous page
…
Page 11
Page 12
Current page 13
Page 14
Page 15
…
Next page
Last page